Shares of Athenex Inc (NASDAQ:ATNX) have received an average recommendation of “Hold” from the eight ratings firms that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $26.80.

A number of brokerages have recently issued reports on ATNX. Zacks Investment Research upgraded shares of Athenex from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Friday, June 8th. BidaskClub lowered shares of Athenex from a “buy” rating to a “hold” rating in a research note on Saturday, May 26th. Finally, ValuEngine lowered shares of Athenex from a “buy” rating to a “hold” rating in a research note on Wednesday, June 27th.

In related news, Director Song-Yi Zhang sold 102,734 shares of the stock in a transaction dated Wednesday, August 22nd. The shares were sold at an average price of $17.24, for a total transaction of $1,771,134.16. Following the sale, the director now owns 4,000 shares in the company, valued at $68,960. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Johnson Yiu Nam Lau acquired 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 6th. The shares were acquired at an average price of $15.84 per share, for a total transaction of $79,200.00. Following the purchase, the chief executive officer now owns 2,825,422 shares of the company’s stock, valued at $44,754,684.48. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 12,500 shares of company stock worth $205,425 and have sold 344,317 shares worth $5,859,972. 29.50% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC raised its stake in Athenex by 426.5% during the first quarter. Barclays PLC now owns 5,913 shares of the company’s stock worth $100,000 after acquiring an additional 4,790 shares during the period. Legal & General Group Plc raised its stake in Athenex by 363.2% during the second quarter. Legal & General Group Plc now owns 6,930 shares of the company’s stock worth $129,000 after acquiring an additional 5,434 shares during the period. Jane Street Group LLC bought a new position in Athenex in the 1st quarter worth about $208,000. Private Advisor Group LLC grew its position in Athenex by 47.5% in the 1st quarter. Private Advisor Group LLC now owns 15,266 shares of the company’s stock worth $260,000 after purchasing an additional 4,915 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY bought a new position in Athenex in the 2nd quarter worth about $266,000. Hedge funds and other institutional investors own 19.82% of the company’s stock.

ATNX stock traded up $0.38 during trading on Tuesday, reaching $16.51. The stock had a trading volume of 292,924 shares, compared to its average volume of 244,278. The firm has a market capitalization of $1.08 billion, a P/E ratio of -7.12 and a beta of -1.75. Athenex has a 1-year low of $13.28 and a 1-year high of $20.90.

Athenex (NASDAQ:ATNX) last issued its earnings results on Tuesday, August 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.10). The company had revenue of $11.57 million during the quarter. Athenex had a negative net margin of 122.29% and a negative return on equity of 73.37%. research analysts predict that Athenex will post -2 EPS for the current fiscal year.

Athenex Company Profile

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

See Also: Moving Average (MA)

Analyst Recommendations for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.